Xcorporeal, Inc.
Xcorporeal, Inc. (XCRP) Stock Competitors & Peer Comparison
See (XCRP) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XCRP | $0.00 | -0.00% | 1.5K | N/A | -$0.20 | N/A |
| BMXXY | $14.55 | +0.00% | 17.2B | 39.32 | $0.37 | +0.68% |
| EBOSY | $35.03 | +0.00% | 1.8B | 24.67 | $1.42 | +3.22% |
| XVIPY | $6.54 | +0.00% | 824M | N/A | N/A | N/A |
| AVNBF | $24.00 | +0.00% | 703.5M | 70.59 | $0.34 | +1.02% |
| EBRCZ | $0.55 | +0.00% | 412.5M | -4.61 | -$0.12 | N/A |
| TRXDW | $0.15 | -11.76% | 40.1M | N/A | N/A | N/A |
| NVNBW | $0.01 | +0.00% | 141.5K | -0.00 | -$1.95 | N/A |
| GWPC | $0.00 | +0.00% | 52K | -0.01 | -$0.01 | N/A |
| SXHHF | $0.00 | +0.00% | 38.1K | -0.01 | -$0.01 | N/A |
Stock Comparison
XCRP vs BMXXY Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, BMXXY has a market cap of 17.2B. Regarding current trading prices, XCRP is priced at $0.00, while BMXXY trades at $14.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas BMXXY's P/E ratio is 39.32. In terms of profitability, XCRP's ROE is -3.49%, compared to BMXXY's ROE of +0.09%. Regarding short-term risk, XCRP and BMXXY have similar daily volatility (0.00).Check BMXXY's competition here
XCRP vs EBOSY Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, EBOSY has a market cap of 1.8B. Regarding current trading prices, XCRP is priced at $0.00, while EBOSY trades at $35.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas EBOSY's P/E ratio is 24.67. In terms of profitability, XCRP's ROE is -3.49%, compared to EBOSY's ROE of +0.06%. Regarding short-term risk, XCRP and EBOSY have similar daily volatility (0.00).Check EBOSY's competition here
XCRP vs XVIPY Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, XVIPY has a market cap of 824M. Regarding current trading prices, XCRP is priced at $0.00, while XVIPY trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas XVIPY's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to XVIPY's ROE of +0.05%. Regarding short-term risk, XCRP and XVIPY have similar daily volatility (0.00).Check XVIPY's competition here
XCRP vs AVNBF Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, AVNBF has a market cap of 703.5M. Regarding current trading prices, XCRP is priced at $0.00, while AVNBF trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas AVNBF's P/E ratio is 70.59. In terms of profitability, XCRP's ROE is -3.49%, compared to AVNBF's ROE of +0.05%. Regarding short-term risk, XCRP and AVNBF have similar daily volatility (0.00).Check AVNBF's competition here
XCRP vs EBRCZ Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, EBRCZ has a market cap of 412.5M. Regarding current trading prices, XCRP is priced at $0.00, while EBRCZ trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas EBRCZ's P/E ratio is -4.61. In terms of profitability, XCRP's ROE is -3.49%, compared to EBRCZ's ROE of -2.35%. Regarding short-term risk, XCRP and EBRCZ have similar daily volatility (0.00).Check EBRCZ's competition here
XCRP vs TRXDW Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, TRXDW has a market cap of 40.1M. Regarding current trading prices, XCRP is priced at $0.00, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas TRXDW's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to TRXDW's ROE of -1.18%. Regarding short-term risk, XCRP and TRXDW have similar daily volatility (0.00).Check TRXDW's competition here
XCRP vs NVNBW Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, NVNBW has a market cap of 141.5K. Regarding current trading prices, XCRP is priced at $0.00, while NVNBW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas NVNBW's P/E ratio is -0.00. In terms of profitability, XCRP's ROE is -3.49%, compared to NVNBW's ROE of -0.61%. Regarding short-term risk, XCRP is less volatile compared to NVNBW. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check NVNBW's competition here
XCRP vs GWPC Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, GWPC has a market cap of 52K. Regarding current trading prices, XCRP is priced at $0.00, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas GWPC's P/E ratio is -0.01. In terms of profitability, XCRP's ROE is -3.49%, compared to GWPC's ROE of N/A. Regarding short-term risk, XCRP and GWPC have similar daily volatility (0.00).Check GWPC's competition here
XCRP vs SXHHF Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, SXHHF has a market cap of 38.1K. Regarding current trading prices, XCRP is priced at $0.00, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, XCRP's ROE is -3.49%, compared to SXHHF's ROE of +1.13%. Regarding short-term risk, XCRP is less volatile compared to SXHHF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check SXHHF's competition here
XCRP vs DGCRF Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, DGCRF has a market cap of 21.5K. Regarding current trading prices, XCRP is priced at $0.00, while DGCRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas DGCRF's P/E ratio is 0.00. In terms of profitability, XCRP's ROE is -3.49%, compared to DGCRF's ROE of -1.11%. Regarding short-term risk, XCRP is less volatile compared to DGCRF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check DGCRF's competition here
XCRP vs KKUR Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, KKUR has a market cap of 8.2K. Regarding current trading prices, XCRP is priced at $0.00, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas KKUR's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to KKUR's ROE of N/A. Regarding short-term risk, XCRP is less volatile compared to KKUR. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check KKUR's competition here
XCRP vs SCIE Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, SCIE has a market cap of 4.9K. Regarding current trading prices, XCRP is priced at $0.00, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas SCIE's P/E ratio is -0.00. In terms of profitability, XCRP's ROE is -3.49%, compared to SCIE's ROE of +0.51%. Regarding short-term risk, XCRP and SCIE have similar daily volatility (0.00).Check SCIE's competition here
XCRP vs OMRX Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, OMRX has a market cap of 4.7K. Regarding current trading prices, XCRP is priced at $0.00, while OMRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas OMRX's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to OMRX's ROE of -0.15%. Regarding short-term risk, XCRP and OMRX have similar daily volatility (0.00).Check OMRX's competition here
XCRP vs IBXG Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, IBXG has a market cap of 2K. Regarding current trading prices, XCRP is priced at $0.00, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas IBXG's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to IBXG's ROE of N/A. Regarding short-term risk, XCRP and IBXG have similar daily volatility (0.00).Check IBXG's competition here
XCRP vs DMSI Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, DMSI has a market cap of 1.9K. Regarding current trading prices, XCRP is priced at $0.00, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas DMSI's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to DMSI's ROE of -0.32%. Regarding short-term risk, XCRP and DMSI have similar daily volatility (0.00).Check DMSI's competition here
XCRP vs AAXT Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, AAXT has a market cap of 1.6K. Regarding current trading prices, XCRP is priced at $0.00, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas AAXT's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to AAXT's ROE of +0.54%. Regarding short-term risk, XCRP and AAXT have similar daily volatility (0.00).Check AAXT's competition here
XCRP vs BMGP Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, BMGP has a market cap of 1.3K. Regarding current trading prices, XCRP is priced at $0.00, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas BMGP's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to BMGP's ROE of -0.50%. Regarding short-term risk, XCRP and BMGP have similar daily volatility (0.00).Check BMGP's competition here
XCRP vs IMRSQ Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, IMRSQ has a market cap of 626. Regarding current trading prices, XCRP is priced at $0.00, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to IMRSQ's ROE of -1.30%. Regarding short-term risk, XCRP and IMRSQ have similar daily volatility (0.00).Check IMRSQ's competition here
XCRP vs STBV Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, STBV has a market cap of 471. Regarding current trading prices, XCRP is priced at $0.00, while STBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas STBV's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to STBV's ROE of -1.13%. Regarding short-term risk, XCRP and STBV have similar daily volatility (0.00).Check STBV's competition here
XCRP vs OMDD Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, OMDD has a market cap of 310. Regarding current trading prices, XCRP is priced at $0.00, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas OMDD's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to OMDD's ROE of N/A. Regarding short-term risk, XCRP and OMDD have similar daily volatility (0.00).Check OMDD's competition here
XCRP vs QMED Comparison February 2026
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, QMED has a market cap of 17. Regarding current trading prices, XCRP is priced at $0.00, while QMED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas QMED's P/E ratio is -0.00. In terms of profitability, XCRP's ROE is -3.49%, compared to QMED's ROE of N/A. Regarding short-term risk, XCRP and QMED have similar daily volatility (0.00).Check QMED's competition here